CTLA4 and hypophysitis: In particular, hypophysitis is more common in patients treated with CTLA-4 inhibitors, while thyroid, adrenal, and pancreas-related side effects are more common with PD-1/PD-L1 inhibitors; the incidence of e-irAEs increases with the combination of PD-1 and CTLA-4 inhibitors [14].